Benjafield Adam V, Oldstone Liesl M, Willes Leslee A, Kelly Colleen, Nunez Carlos M, Malhotra Atul
ResMed Science Center, San Diego, CA 92123, USA.
Willes Consulting, Encinitas, CA 92024, USA.
J Clin Med. 2021 Feb 12;10(4):720. doi: 10.3390/jcm10040720.
There are currently few data on the impact of mask resupply on longer-term adherence to positive airway pressure (PAP) therapy. This retrospective analysis investigated the effects of mask/mask cushion resupply on the adherence to PAP versus no resupply. Deidentified patient billing data for PAP supply items were merged with telemonitoring data from Cloud-connected AirSense 10/AirCurve 10 devices via AirView (ResMed). Eligible patients started PAP between 1 July 2014 and 17 June 2016, had ≥360 days of PAP device data, and achieved initial U.S. Medicare adherence criteria. Patients who received a resupply of mask systems/cushions (resupply group) were propensity-score-matched with those not receiving any mask/cushion resupply (control group). A total of 100,370 patients were included. From days 91 to 360, the mean device usage was 5.6 and 4.5 h/night in the resupply and control groups, respectively ( < 0.0001). The proportion of patients with a mean device usage ≥4 h/night was significantly higher in the resupply group versus the control group (77% vs. 59%; < 0.0001). The therapy termination rate was significantly lower in the resupply group versus the control group (14.7% vs. 31.9%; < 0.0001); there was a trend toward lower therapy termination rates as the number of resupplies increased. The replacement of mask interface components was associated with better longer-term adherence to PAP therapy versus no resupply.
目前,关于面罩再供应对长期坚持气道正压通气(PAP)治疗的影响的数据较少。这项回顾性分析调查了面罩/面罩衬垫再供应对坚持PAP治疗与不进行再供应的影响。通过AirView(瑞思迈公司)将PAP供应项目的去识别患者计费数据与来自云连接的AirSense 10/AirCurve 10设备的远程监测数据合并。符合条件的患者于2014年7月1日至2016年6月17日开始使用PAP,有≥360天的PAP设备数据,并达到美国医疗保险初始依从性标准。接受面罩系统/衬垫再供应的患者(再供应组)与未接受任何面罩/衬垫再供应的患者(对照组)进行倾向得分匹配。共纳入100370名患者。从第91天到第360天,再供应组和对照组的平均设备使用时间分别为每晚5.6小时和4.5小时(<0.0001)。平均设备使用时间≥4小时/晚的患者比例,再供应组显著高于对照组(77%对59%;<0.0001)。再供应组的治疗终止率显著低于对照组(14.7%对31.9%;<0.0001);随着再供应次数的增加,治疗终止率有降低的趋势。与不进行再供应相比,更换面罩接口组件与更好地长期坚持PAP治疗相关。